Hardik Desai Family Trust has increased its shareholding in Trident Lifeline Limited by acquiring 1,200 shares through an open market transaction on June 12, 2026. The acquisition, disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, raises the Trust's stake in the company. The disclosure was submitted by Hardik Jigishkumar Desai, the Ultimate Beneficial Owner (UBO) and Trustee of the Hardik Desai Family Trust, which falls under the promoter group category.

Prior to this transaction, the Trust held 8,56,166 shares, accounting for 7.17% of the total share capital and 6.85% of the total diluted share capital. With the addition of 1,200 shares, the post-acquisition holding stands at 8,57,366 equity shares. This revised holding constitutes 7.18% of the total paid-up voting capital and 6.86% of the total diluted share capital of the target company.

The equity share capital of Trident Lifeline Limited remains at Rs. 11,93,30,000, divided into 1,19,33,000 equity shares of Rs. 10 each. The total diluted share capital, accounting for the full conversion of outstanding convertible securities or warrants, is reported at Rs. 12,49,34,000, comprising 1,24,93,400 equity shares of Rs. 10 each.

The following table details the changes in the shareholding pattern of Hardik Desai Family Trust:

The transaction was executed via the open market route. Trident Lifeline Limited is listed on BSE Ltd with the scrip code 543616. The filing confirms that no shares were encumbered, and no warrants or convertible securities were involved in the transaction. The disclosure was signed and submitted by Hardik Jigishkumar Desai on June 15, 2026.

Trident Lifeline Limited announced a reduction in its shareholding within its subsidiary, Trident Mediquip Limited, to 58.84% following a private placement of equity shares to other shareholders. The disclosure, made to the exchange on June 9, 2026, under Regulation 30 of the SEBI (LODR) Regulations, 2015, highlights a dilution of the parent company's stake from a previous holding of 59.17%. This adjustment impacts the control structure of the subsidiary, which operates within the medical device industry.

The private placement transaction involved related parties, including Mr. Amit Bhupendra Halvawala and Mr. Chetan Chandrakant Jariwala, who are members of the promoter group and board of Trident Lifeline Limited. Despite these connections, the company confirmed that the transaction was conducted on an arm's length basis. The subsidiary, incorporated on October 19, 2019, is based in Surat, Gujarat, and specializes in the medical device sector.

Financial details provided in the filing indicate that Trident Mediquip Limited has an authorized share capital of ₹10,00,00,000 divided into 1,00,00,000 equity shares of ₹10 each. The paid-up share capital stands at ₹9,97,00,000 divided into 99,70,000 equity shares of ₹10 each. The company reported a turnover of ₹27.31 Cr for the financial year 2025-26, showing growth from ₹20.58 Cr in 2023-24 and ₹21.29 Cr in 2024-25.

Shareholding Details

The change in ownership structure is detailed in the table below:

Subsidiary Overview

Trident Mediquip Limited operates exclusively in India. The filing confirms that no specific governmental or regulatory approvals were required for this acquisition, nor were there any indicative time periods or cash considerations disclosed for the completion of the private placement. The subsidiary's performance over the last three years reflects a steady upward trajectory in its financial operations.